WILMINGTON, Del., Sept. 05, 2018 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB), announced today that Jonathan Javitt, M.D., M.P.H., the Company’s Chief Executive Officer and Chairman, will update investors on the Company’s progress towards the planned […]

WILMINGTON, De. , Sept. 04, 2018 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB), announced today initial top-line data from the Phase 2 STABIL-B trial. The STABIL-B study is a company-sponsored Phase 2 clinical trial to test […]

WILMINGTON, Del.–(BUSINESS WIRE)– NeuroRx, Inc., a clinical stage biopharma company has completed the feasibility enrollment phase of its 2b/3 clinical trial of NRX-101 for the treatment of suicidal bipolar depression. The study is designed to test the hypothesis that NRX-101 is superior to standard of care in maintaining remission from depression and suicidal ideation in […]

FDA deems proposed Phase 2b/3 trial adequate to support a regulatory submission WILMINGTON, Del., May 07, 2018 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation and Behavior (ASIB), has been awarded a Special Protocol  Agreement letter by the […]

Company to present at J.P. Morgan Healthcare Conference in San Francisco January 10th, 2018 WILMINGTON, Del., Jan. 3, 2018 /PRNewswire/ — NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB), announced that it has retained J.P. Morgan as financial […]

Third clinical research site for NRX-100 / NRX-101 phase 2B/3 clinical study WILMINGTON, Del., Dec. 27, 2017 /PRNewswire/ — NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB), announced that it has signed a Cooperative Research and Development Agreement (CRADA) […]

Company to present at Rodman and Renshaw Global Investment Conference in New York City on Sept 12, 2017 WILMINGTON, Del., Sept. 6, 2017 /PRNewswire/ — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug […]

Recent hospitalization is a risk factor for further suicide attempts — potentially related to patient care perceptions WILMINGTON, Del.–(BUSINESS WIRE)– NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental health advocates and expert opinion leaders. The strictly anonymous survey, seeking […]

Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression Wilmington, Delaware , March 24, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, […]

Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression Wilmington, Delaware , March 20, 2017 (GLOBE NEWSWIRE) — NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that Jonathan Javitt, M.D., M.P.H., Chief Executive Officer, […]